The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis
- PMID: 33301825
- DOI: 10.1016/j.jhep.2020.11.048
The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis
Abstract
Acute decompensation (AD) of cirrhosis is defined by the development of ascites, hepatic encephalopathy and/or variceal bleeding. Ascites is traditionally attributed to splanchnic arterial vasodilation and left ventricular dysfunction, hepatic encephalopathy to hyperammonaemia, and variceal haemorrhage to portal hypertension. Recent large-scale European observational studies have shown that systemic inflammation is a hallmark of AD. Here we present a working hypothesis, the systemic inflammation hypothesis, suggesting that systemic inflammation through an impairment of the functions of one or more of the major organ systems may be a common theme and act synergistically with the traditional mechanisms involved in the development of AD. Systemic inflammation may impair organ system function through mechanisms which are not mutually exclusive. The first mechanism is a nitric oxide-mediated accentuation of the preexisting splanchnic vasodilation, resulting in the overactivation of the endogenous vasoconstrictor systems which elicit intense vasoconstriction and hypoperfusion in certain vascular beds, in particular the renal circulation. Second, systemic inflammation may cause immune-mediated tissue damage, a process called immunopathology. Finally, systemic inflammation may induce important metabolic changes. Indeed, systemic inflammatory responses are energetically expensive processes, requiring reallocation of nutrients (glucose, amino acids and lipids) to fuel immune activation. Systemic inflammation also inhibits nutrient consumption in peripheral (non-immune) organs, an effect that may provide one mechanism of reallocation and prioritisation of metabolic fuels for inflammatory responses. However, the decrease in nutrient consumption in peripheral organs may result in decreased mitochondrial production of ATP (energy) and subsequently impaired organ function.
Keywords: ACLF; Acute-on-chronic liver failure; Bacterial infections; Metabolism; Pre-ACLF; Stable decompensated cirrhosis; Systemic inflammation; Unstable decompensated cirrhosis.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest Rajiv Jalan has research collaborations with Yaqrit and Takeda. Rajiv Jalan is the inventor of OPA, which has been patented by UCL and licensed to Mallinckrodt Pharma. He is also the founder of Yaqrit Ltd. (a spin-out company from University College London), Thoeris GmbH, Cyberliver Ltd. and Hepyx Ltd. None of the other authors have conflicts of interest in relation to the reported study. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome.J Hepatol. 2021 May;74(5):1264-1265. doi: 10.1016/j.jhep.2020.12.017. Epub 2021 Mar 9. J Hepatol. 2021. PMID: 33347950 No abstract available.
-
Systemic inflammation and liver cirrhosis complications: Driving or secondary event? How to square the circle?J Hepatol. 2021 Mar;74(3):508-510. doi: 10.1016/j.jhep.2021.01.001. Epub 2021 Jan 18. J Hepatol. 2021. PMID: 33478857 No abstract available.
-
Reply to: "Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome".J Hepatol. 2021 May;74(5):1265-1267. doi: 10.1016/j.jhep.2021.02.021. Epub 2021 Feb 25. J Hepatol. 2021. PMID: 33640401 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical